Trials / Unknown
UnknownNCT00435799
Evaluating Collagen Cross-Linking (CCL) Treatment in Norway
Treatment of Keratectasia With Collagen Cross-Linking (CCL) at the Eye Departments of the University Hospital, North Norway in Tromsø and Ullevål University Hospital in Oslo
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Ullevaal University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.
Detailed description
The technique of corneal collagen cross-linking consists of photopolymerization of stromal fibers by combined action of a photosensitizing substance, riboflavin and ultraviolet type A rays (UVA) from a solid-state UVA Source. Photopolymerization increases the rigidity of corneal collagen and its resistance to keratectasia. It has been used to stop progression of keratectasia. Corneal transplantation has been the only available option so far for treatment for keratectasia in its advanced stage in Norway. The method of CCL using riboflavin and UV light is technically simple and much less invasive than corneal transplantation and it treats and prevents the underlying pathophysiological mechanism. It also does not reduce the chances for a successful corneal transplantation, in case that would still be necessary after CCL. The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | corneal cross-linking (CCL) | |
| DRUG | Riboflavin/dextran eyedrops | |
| DEVICE | UV-X system |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-01-01
- Completion
- 2010-01-01
- First posted
- 2007-02-15
- Last updated
- 2008-06-10
Locations
2 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT00435799. Inclusion in this directory is not an endorsement.